Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity
Source: SeekingAlpha
2025-12-10 13:43:43 ET
More on Dyne Therapeutics, Avidity Biosciences
- Dyne Therapeutics: Why The $350M Public Offering Was Critical
- Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy Transcript
- Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy - Slideshow
- Dyne Therapeutics prices $350 stock offering
- Dyne Therapeutics announces $300M proposed public offering
Read the full article on Seeking Alpha
For further details see:
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity
Dyne Therapeutics Inc.
NASDAQ: DYN
DYN Trading
6.14% G/L:
$18.50 Last:
491,992 Volume:
$18.15 Open:
DYN Latest News
June 03, 2026 07:30:00 am
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
May 26, 2026 07:30:00 am
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
May 25, 2026 06:56:40 pm
Dyne Spikes as Phase 3 Duchenne Trial Launch Strengthens Path Toward Potential 2027 Approval
DYN Stock Data
$2,792,339,585
138,744,373
0.04%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
